alcohol associated liver disease epidemiology forecast
Key Highlights
- According to DelveInsight’s analysis, the total diagnosed prevalent cases were approximately 12.1 million in the leading markets (the United States, the EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan) in 2025.
- ALD is a chronic, progressive spectrum of liver disorders caused by sustained excessive alcohol consumption, resulting in metabolic dysregulation, inflammation, fibrosis, and irreversible structural liver damage. It is one of the leading causes of liver-related morbidity and mortality globally and accounts for approximately half of cirrhosis cases in the United States. ALD significantly impairs survival, quality of life, and healthcare systems due to frequent hospitalizations, complications, and limited therapeutic options.
- According to the World Health Organization, alcohol consumption accounted for an estimated 2.6 million deaths globally in 2019, with ALD representing a significant contributor to this burden.
- Higher prevalence of ALD among Asian populations, as well as in individuals with higher education levels and daily smoking habits, indicates that risk is shaped by a complex interplay of genetic, cultural, and behavioral factors beyond alcohol exposure alone.
- The global prevalence of ALD varies considerably across regions, closely mirroring patterns of alcohol consumption. The burden is particularly high in parts of Europe and the America, where elevated intake levels, shaped by cultural norms, socioeconomic factors, and drinking behaviour, drive disproportionately higher disease incidence.
- ALD shows a marked gender disparity, with males predominating, likely due to higher alcohol exposure and risk behaviors. Most patients are diagnosed before advanced fibrosis, often with moderate steatosis, highlighting a key window for early intervention, while those with advanced fibrosis or severe steatosis carry disproportionately high risks of complications, hospitalization, and liver transplantation.
Alcohol-associated Liver Disease (ALD) Epidemiology Forecast in the 7MM
- 2025 Diagnosed Prevalent Cases of ALD: ~12.1 million
- 2036 Projected Diagnosed Prevalent Cases of ALD: ~13.0 million
- ALD Growth Rate (2026–2036): 0.7% CAGR
DelveInsight's ‘Alcohol-associated Liver Disease (ALD) – Epidemiology Forecast – 2036’ report delivers an in-depth understanding of the Alcohol-associated Liver Disease (ALD), historical and forecasted epidemiology in the United States, EU4 (Germany, Spain, Italy, and France) and the United Kingdom, and Japan.
|
Study Period
|
2022–2036
|
|
Historical Year
|
2022–2025
|
|
Forecast Period
|
2026–2036
|
|
Base Year
|
2026
|
|
Geographies Covered
|
- North America : The US;
- Europe: Germany, France, Italy, Spain and the UK;
- Asia-Pacific: Japan
|
|
ALD Epidemiology CAGR (Forecast period)
|
0.7% (2026–2036)
|
|
ALD Epidemiology Segmentation Analysis
|
Patient Burden Assessment
- Total Diagnosed Prevalent Cases of ALD
- Stage-specific Diagnosed Prevalent Cases of ALD
- Gender-specific Diagnosed Prevalent Cases of ALD
- Diagnosed Prevalent Cases of ALD by Fibrosis Stage
- Diagnosed Prevalent Cases of ALD by Fatty Liver Grade
- Total Prevalent Cases of AUD in ALD
- Total Treated Cases of ALD
|
Alcohol-associated Liver Disease (ALD) Understanding and Diagnosis
Alcohol-associated Liver Disease (ALD) Overview
ALD is a progressive spectrum of chronic liver injury driven by prolonged excessive alcohol intake and remains a leading cause of liver-related morbidity and mortality globally. It ranges from early-stage steatosis, characterized by fat accumulation in hepatocytes, to more severe conditions such as alcohol-associated steatohepatitis (ASH), fibrosis, cirrhosis, and hepatocellular carcinoma (HCC), with some patients developing acute alcohol-associated hepatitis marked by high short-term mortality. Pathophysiologically, alcohol metabolism in the liver disrupts metabolic homeostasis, inducing oxidative stress, lipid dysregulation, inflammation, and hepatocellular damage. While steatosis occurs in most heavy drinkers, only a subset progress to advanced disease, reflecting the complex interplay of metabolic, inflammatory, and fibrotic pathways underlying ALD progression.
Further details are provided in the report…
Diagnosis
Diagnosis of alcohol-associated hepatitis is largely clinical and supported by laboratory findings such as elevated bilirubin levels, increased Aspartate Aminotransferase (AST), and a characteristic AST/ALT ratio >1.5. Severe forms of alcoholic hepatitis are associated with high short-term mortality and limited therapeutic options.
Further details are provided in the report…
Alcohol-associated Liver Disease (ALD) Epidemiology
Key Findings from Alcohol-associated Liver Disease (ALD) Epidemiological Analysis and Forecast
- According to DelveInsight’s estimates, in 2025, the total number of diagnosed prevalent cases of ALD in the 7MM were ~12.1 million.
- In the US, among stage-specific diagnosed prevalent cases of ALD, alcohol-associated steatosis accounted for the majority of cases (~3,214,800) in 2025, followed by alcohol-associated steatohepatitis (918,500 cases), and alcohol-associated cirrhosis (459,300 cases), in 2025.
- In Japan, males accounted the higher number of ALD cases, with approximately 2.26 million cases as compared to females.
- Stage-specific analysis of ALD reveals a predominance of patients in early disease stages, particularly alcohol-associated steatosis, with progressively fewer individuals advancing to steatohepatitis and cirrhosis. This distribution reflects the natural, gradual progression of ALD, in which only a subset of patients develop severe, irreversible liver damage. The substantial early-stage population underscores a critical window for intervention, whereas the smaller cohort with advanced disease drives a disproportionate share of morbidity, mortality, and healthcare resource utilization.
Scope of the Report
- The report covers a segment of key events, an executive summary, a descriptive overview of Alcohol-associated Liver Disease (ALD), explaining their causes, signs and symptoms, and pathogenesis.
- Comprehensive insight has been provided into the epidemiology segments and forecasts, the future growth potential of the diagnosis rate, and disease progression.
Report Insights
- Alcohol-associated Liver Disease (ALD) Patient Population Forecast
Report Key Strengths
- Epidemiology-based (Epi-based) Bottom-up Forecasting
- 11-Year Forecast
- Patient Burden Trends (By Geography)
FAQs
- What are the disease risks, burdens, and unmet needs of Alcohol-associated Liver Disease (ALD)? What will be the growth opportunities across the 7MM concerning the patient population with Alcohol-associated Liver Disease (ALD)?
- What is the historical and forecasted Alcohol-associated Liver Disease (ALD) patient pool in the US, EU4 (Germany, France, Italy, and Spain), the UK, and Japan?
Reasons to Buy
- Insights on patient burden/disease prevalence, evolution in diagnosis, and factors contributing to the change in the epidemiology of the disease during the forecast years.
- To understand key opinion leaders’ perspectives around the diagnostic challenges to overcome barriers in the future.
- Detailed insights on various factors hampering disease diagnosis and other existing diagnostic challenges.
1. Key Insights
2. Report Introduction
3. Executive Summary
4. Epidemiology Forecast Methodology
5. ALD Overview at a Glance
5.1. Patient Share (%) Distribution by Country in 2025 in the 7MM
5.2. Patient Share (%) Distribution by Country in 2036 in the 7MM
6. Disease Background and Overview
6.1. Introduction
6.2. Stages of ALD
6.2.1. Stage 1: Alcohol-associated Steatosis (Fatty Liver)
6.2.2. Stage 2: Alcohol-associated Hepatitis (Alcoholic Hepatitis)
6.2.3. Stage 3: Alcohol-associated Cirrhosis
6.3. Signs and Symptoms
6.3.1. Common Symptoms
6.3.2. Physical Signs (Examination findings)
6.4. Pathophysiology of ALD
6.5. Pathogenesis of ALD
6.6. Causes and Risk Factors of ALD
6.7. Differential Diagnosis
6.8. Diagnosis
6.8.1. Diagnostic Algorithm
7. Epidemiology and Patient Population
7.1. Key Findings
7.2. Assumptions and Rationale
7.3. Total Diagnosed Prevalent Cases of ALD in the 7MM
7.4. The United States
7.4.1. Total Diagnosed Prevalent Cases of ALD in the United States
7.4.2. Stage-specific Diagnosed Prevalent Cases of ALD in the United States
7.4.3. Gender-specific Diagnosed Prevalent Cases of ALD in the United States
7.4.4. Diagnosed Prevalent Cases of ALD by Fibrosis Stage in the United States
7.4.5. Diagnosed Prevalent Cases of ALD by Fatty Liver Grade in the United States
7.4.6. Total Prevalent Cases of AUD in ALD in the United States
7.4.7. Treated Cases of ALD in the United States
7.5. EU4 and the UK
7.5.1. Total Diagnosed Prevalent Cases of ALD in EU4 and the UK
7.5.2. Stage-specific Diagnosed Prevalent Cases of ALD in EU4 and the UK
7.5.3. Gender-specific Diagnosed Prevalent Cases of ALD in EU4 and the UK
7.5.4. Diagnosed Prevalent Cases of ALD by Fibrosis Stage in EU4 and the UK
7.5.5. Diagnosed Prevalent Cases of ALD by Fatty Liver Grade in EU4 and the UK
7.5.6. Total Prevalent Cases of AUD in ALD in EU4 and the UK
7.5.7. Treated Cases of ALD in EU4 and the UK
7.6. Japan
7.6.1. Total Diagnosed Prevalent Cases of ALD in Japan
7.6.2. Stage-specific Diagnosed Prevalent Cases of ALD in Japan
7.6.3. Gender-specific Diagnosed Prevalent Cases of ALD in Japan
7.6.4. Diagnosed Prevalent Cases of ALD by Fibrosis Stage in Japan
7.6.5. Diagnosed Prevalent Cases of ALD by Fatty Liver Grade in Japan
7.6.6. Total Prevalent Cases of AUD in ALD in Japan
7.6.7. Treated Cases of ALD in Japan
8. Appendix
8.1. Bibliography
8.2. Report Methodology
9. DelveInsight Capabilities
10. Disclaimer
11. About DelveInsight
List of Tables:
List of Table
Table 1: Summary of ALD Epidemiology
Table 2: Recommendations by the ACG
Table 3: Guidance Statements by the AASLD
Table 4: EASL Clinical Practice Guidelines: Screening of ALD (2018)
Table 5: Total Diagnosed Prevalent Cases of ALD in the 7MM (2022–2036)
Table 6: Total Diagnosed Prevalent Cases of ALD in the United States (2022–2036)
Table 7: Stage-specific Diagnosed Prevalent Cases of ALD in the United States (2022–2036)
Table 8: Gender-specific Diagnosed Prevalent Cases of ALD in the United States (in Thousands) (2022–2036)
Table 9: Diagnosed Prevalent Cases of ALD by Fibrosis Stage in the United States (2022–2036)
Table 10: Diagnosed Prevalent Cases of ALD by Fatty Liver Grade in the United States (2022–2036)
Table 11: Total Prevalent Cases of AUD in ALD in the United States (2022–2036)
Table 12: Treated Cases of ALD in the United States (2022–2036)
Table 13: Total Diagnosed Prevalent Cases of ALD in EU4 and the UK (2022–2036)
Table 14: Stage-specific Diagnosed Prevalent Cases of ALD in Germany (2022–2036)
Table 15: Stage-specific Diagnosed Prevalent Cases of ALD in France (2022–2036)
Table 16: Stage-specific Diagnosed Prevalent Cases of ALD in Italy (2022–2036)
Table 17: Stage-specific Diagnosed Prevalent Cases of ALD in Spain (2022–2036)
Table 18: Stage-specific Diagnosed Prevalent Cases of ALD in the UK (2022–2036)
Table 19: Stage-specific Diagnosed Prevalent Cases of ALD in EU4 and the UK (2022–2036)
Table 20: Gender-specific Diagnosed Prevalent Cases of ALD in Germany (2022–2036)
Table 21: Gender-specific Diagnosed Prevalent Cases of ALD in France (2022–2036)
Table 22: Gender-specific Diagnosed Prevalent Cases of ALD in Italy (2022–2036)
Table 23: Gender-specific Diagnosed Prevalent Cases of ALD in Spain (2022–2036)
Table 24: Gender-specific Diagnosed Prevalent Cases of ALD in the UK (2022–2036)
Table 25: Gender-specific Diagnosed Prevalent Cases of ALD in EU4 and the UK (2022–2036)
Table 26: Diagnosed Prevalent Cases of ALD by Fibrosis Stage in Germany (2022–2036)
Table 27: Diagnosed Prevalent Cases of ALD by Fibrosis Stage in France (2022–2036)
Table 28: Diagnosed Prevalent Cases of ALD by Fibrosis Stage in Italy (2022–2036)
Table 29: Diagnosed Prevalent Cases of ALD by Fibrosis Stage in Spain (2022–2036)
Table 30: Diagnosed Prevalent Cases of ALD by Fibrosis Stage in the UK (2022–2036)
Table 31: Diagnosed Prevalent Cases of ALD by Fibrosis Stage in EU4 and the UK (2022–2036)
Table 32: Diagnosed Prevalent Cases of ALD by Fatty Liver Grade in Germany (2022–2036)
Table 33: Diagnosed Prevalent Cases of ALD by Fatty Liver Grade in France (2022–2036)
Table 34: Diagnosed Prevalent Cases of ALD by Fatty Liver Grade in Italy (2022–2036)
Table 35: Diagnosed Prevalent Cases of ALD by Fatty Liver Grade in Spain (2022–2036)
Table 36: Diagnosed Prevalent Cases of ALD by Fatty Liver Grade in the UK (2022–2036)
Table 37: Diagnosed Prevalent Cases of ALD by Fatty Liver Grade in EU4 and the UK (2022–2036)
Table 38: Total Prevalent Cases of AUD in ALD in EU4 and the UK (2022–2036)
Table 39: Treated Cases of ALD in EU4 and the UK (2022–2036)
Table 40: Total Diagnosed Prevalent Cases of ALD in Japan (2022–2036)
Table 41: Stage-specific Diagnosed Prevalent Cases of ALD in Japan (2022–2036)
Table 42: Gender-specific Diagnosed Prevalent Cases of ALD in Japan (2022–2036)
Table 43: Diagnosed Prevalent Cases of ALD by Fibrosis Stage in Japan (2022–2036)
Table 44: Diagnosed Prevalent Cases of ALD by Fatty Liver Grade in the Japan (2022–2036)
Table 45: Total Prevalent Cases of AUD in ALD in Japan (2022–2036)
Table 46: Treated Cases of ALD in Japan (2022–2036)
List of Figures:
List of Figures
Figure 1: Spectrum of ALD
Figure 2: Symptoms of ALD
Figure 3: Schematic Depiction of the Role of Kupffer Cells (KCs) and Hepatic Stellate Cells (HSCs) in Promoting Alcohol-induced Inflammatory Changes and Progression to Fibrosis and Cirrhosis
Figure 4: Hepatic Metabolism of Ethanol Associated With Oxidative Stress
Figure 5: Pathogenesis of ALD
Figure 6: Risk Factors
Figure 7: Health Gradient in Alcohol-related liver disease
Figure 8: Differential Diagnosis of ALD
Figure 9: Diagnostic Algorithm of ALD
Figure 10: Total Diagnosed Prevalent Cases of ALD in the 7MM (2022–2036)
Figure 11: Total Diagnosed Prevalent Cases of ALD in the United States (2022–2036)
Figure 12: Stage-specific Diagnosed Prevalent Cases of ALD in the United States (2022–2036)
Figure 13: Gender-specific Diagnosed Prevalent Cases of ALD in the United States (2022–2036)
Figure 14: Diagnosed Prevalent Cases of ALD by Fibrosis Stage in the United States (2022–2036)
Figure 15: Diagnosed Prevalent Cases of ALD by Fatty Liver Grade in the United States (2022–2036)
Figure 16: Total Prevalent Cases of AUD in ALD in the United States (2022–2036)
Figure 17: Treated Cases of ALD in the United States (2022–2036)
Figure 18: Total Diagnosed Prevalent Cases of ALD in EU4 and the UK (2022–2036)
Figure 19: Stage-specific Diagnosed Prevalent Cases of ALD in EU4 and the UK (2022–2036)
Figure 20: Gender-specific Diagnosed Prevalent Cases of ALD in EU4 and the UK (2022–2036)
Figure 21: Diagnosed Prevalent Cases of ALD by Fibrosis Stage in EU4 and the UK (2022–2036)
Figure 22: Diagnosed Prevalent Cases of ALD by Fatty Liver Grade in EU4 and the UK (2022–2036)
Figure 23: Total Prevalent Cases of AUD in ALD in EU4 and the UK (2022–2036)
Figure 24: Treated Cases of ALD in EU4 and the UK (2022–2036)
Figure 25: Total Diagnosed Prevalent Cases of ALD in Japan (2022–2036)
Figure 26: Stage-specific Diagnosed Prevalent Cases of ALD in Japan (2022–2036)
Figure 27: Gender-specific Diagnosed Prevalent Cases of ALD in Japan (2022–2036)
Figure 28: Diagnosed Prevalent Cases of ALD by Fibrosis Stage in Japan (2022–2036)
Figure 29: Diagnosed Prevalent Cases of ALD by Fatty Liver Grade in Japan (2022–2036)
Figure 30: Total Prevalent Cases of AUD in ALD in Japan (2022–2036)
Figure 31: Treated Cases of ALD in Japan (2022–2036)
Figure 32: Launch Timeline of Emerging Therapies
Figure 33: Total Market Size of ALD in the 7MM (2022–2036)
Figure 34: Total Market Size of ALD in the United States (2022–2036)
Figure 35: Market Size of ALD by Therapies in the United States (2022–2036)
Figure 36: Total Market Size of ALD in EU4 and the UK (2022–2036)
Figure 37: Market Size of ALD by Therapies in EU4 and the UK (2022–2036)
Figure 38: Total Market Size of ALD in Japan (2022–2036)
Figure 39: Market Size of ALD by Therapies in Japan (2022–2036)
